Evommune Inc Dossier
Qualitative Analysis
Business overview
Evommune, Inc. (NYSE: EVMN) is a clinical-stage biotechnology company focused on discovering and developing novel, highly differentiated therapies that target key drivers of chronic inflammatory and autoimmune diseases. The company leverages a proprietary human tissue-based screening platform to curate its drug discovery and translational medicine decisions, aiming to address the root causes of inflammation rather than merely managing symptoms. Evommune's pipeline is anchored by two primary clinical-stage candidates: EVO756, a potent, highly selective, first-in-class oral small molecule antagonist of Mas-related G protein-coupled receptor X2 (MRGPRX2) designed to target mast cells and peripheral sensory neurons; and EVO301, a long-acting injectable IL-18 binding protein fusion protein designed for more effective distribution to inflamed tissues.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the clinical development of EVO756, a potent and highly selective oral small molecule antagonist of MRGPRX2, across multiple indications including chronic spontaneous urticaria, atopic dermatitis, and migraine prophylaxis.
Expected impact: Establishment of a first-in-class oral therapeutic option that modulates both mast cells and sensory neurons to treat chronic inflammatory and pruritic diseases.
Advancing EVO301, a long-acting fusion protein consisting of an IL-18 binding protein and an anti-serum albumin Fab-associated domain, following positive Phase 2a proof-of-concept data.
Expected impact: Development of a highly differentiated biologic therapy for moderate-to-severe atopic dermatitis with potential dosing advantages over existing treatments.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Provides regional development and commercialization capabilities for EVO756 in Japan and Greater Asia, while generating non-dilutive licensing revenue for Evommune.
Terms: Evommune is eligible to receive up to $60.0 million in upfront and customary milestone payments, plus tiered royalties on future sales of EVO756 in Japan under the initial agreement, with subsequent expansion to Greater Asia.
Secured the exclusive global license to develop and commercialize EVO756.
Terms: Evommune paid Dermira a $7.5 million upfront license fee and issued 3,227,805 shares of Series A Preferred Stock (representing approximately 5% of its fully diluted equity at the time). As of December 31, 2025, Evommune had paid a total of $11.0 million in upfront payments and development milestones under the agreement. The company is also obligated to pay up to $45.0 million in development milestones and up to $240.0 million in sales milestones for EVO756 (or up to $135.0 million and $720.0 million, respectively, for all licensed products), plus tiered mid-single digit to low-tens percentage royalties on worldwide sales.
Secured the exclusive global license (excluding South Korea) to develop and commercialize EVO301 (APB-R3).
Terms: Upfront payment of $15.0 million, with potential milestone payments up to $460.0 million upon achievement of future milestones, plus royalties on future sales of EVO301.